X0206 3 2020-10-15 0 0001799448 Aligos Therapeutics, Inc. ALGS 0001388325 Novo Holdings A/S TUBORG HAVNEVEJ 19 HELLERUP G7 2900 DENMARK 0 0 1 0 SERIES A CONVERTIBLE PREFERRED STOCK COMMON STOCK 1609493 D SERIES B-1 CONVERTIBLE PREFERRED STOCK COMMON STOCK 563851 D SERIES B-2 CONVERTIBLE PREFERRED STOCK COMMON STOCK 241219 D Each share of Series A Convertible Preferred Stock, Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock will convert automatically into one share of common stock upon the closing of the Issuer's initial public offering. These shares have no expiration date. Novo Holdings A/S is a Danish limited liability company. The board of directors of Novo Holdings A/S (the "Novo Board") has shared investment and voting control over the securities of the Issuer held by Novo Holdings A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares. /s/ Peter Haahr, Chief Financial Officer of Novo Holdings A/S 2020-10-15